Literature DB >> 28364440

Incidence and predictors of vasoplegia after heart failure surgery.

Marieke E van Vessem1,2, Meindert Palmen2, Lotte E Couperus1, Bart Mertens3, Remco R Berendsen4, Laurens F Tops1, Harriëtte F Verwey1, Evert de Jonge5, Robert J M Klautz2, Martin J Schalij1, Saskia L M A Beeres1.   

Abstract

Objectives: Vasoplegia has been described as a complication after cardiac surgery, particularly in patients with a poor left ventricular ejection fraction. The aim of this study was to assess the incidence, survival and predictors of vasoplegia in patients undergoing heart failure surgery and to propose a risk model.
Methods: A retrospective study including heart failure patients who underwent surgical left ventricular restoration, CorCap implantation or left ventricular assist device implantation between 2006 and 2015. Patients were classified by the presence or absence of vasoplegia.
Results: Two hundred and twenty-five patients were included. The incidence of vasoplegia was 29%. The 90-day survival rate in vasoplegic patients was lower compared with non-vasoplegic patients (71% vs 91%, P  <   0.001). After adjusting for age, sex and surgical procedure, anaemia (OR 2.195; 95% CI 1.146, 4.204; P  =   0.018) and a higher thyroxine level (OR 1.140; 95% CI 1.033, 1.259; P  =   0.009) increased the risk of vasoplegia; a higher creatinine clearance (OR 0.980; 95% CI 0.965, 0.994; P  =   0.006) and beta-blocker use (OR 0.257; 95% CI 0.112, 0.589; P  =   0.001) decreased the risk. The risk model consisted of the same variables and could adequately identify patients at risk for vasoplegia. Conclusions: Vasoplegia after heart failure surgery is common and results in a lower survival rate. Anaemia and a higher thyroxine level are associated with an increased risk on vasoplegia. In contrast, a higher creatinine clearance and beta-blocker use decrease the risk on vasoplegia. These factors are used in the risk model that may guide treatment strategy.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Heart failure; Risk model; Surgery; Vasoplegia; Vasoplegic syndrome

Mesh:

Substances:

Year:  2017        PMID: 28364440     DOI: 10.1093/ejcts/ezw316

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Association between acute kidney injury and norepinephrine use following cardiac surgery: a retrospective propensity score-weighted analysis.

Authors:  Pierre Huette; Mouhamed Djahoum Moussa; Christophe Beyls; Pierre-Grégoire Guinot; Mathieu Guilbart; Patricia Besserve; Mehdi Bouhlal; Sarah Mounjid; Hervé Dupont; Yazine Mahjoub; Audrey Michaud; Osama Abou-Arab
Journal:  Ann Intensive Care       Date:  2022-07-04       Impact factor: 10.318

Review 2.  Vasoplegia from Continuous Flow Left Ventricular Assist Devices.

Authors:  Shyama Sathianathan; Geetha Bhat; Robert Dowling
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

3.  Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors.

Authors:  Eric E C de Waal; Bas van Zaane; Marnix M van der Schoot; Albert Huisman; Faiz Ramjankhan; Wilton A van Klei; Nandor Marczin
Journal:  BMC Anesthesiol       Date:  2018-12-08       Impact factor: 2.217

4.  Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices.

Authors:  Rabea Asleh; Hilmi Alnsasra; Richard C Daly; Sarah D Schettle; Alexandros Briasoulis; Riad Taher; Shannon M Dunlay; John M Stulak; Atta Behfar; Naveen L Pereira; Robert P Frantz; Brooks S Edwards; Alfredo L Clavell; Sudhir S Kushwaha
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

Review 5.  The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia.

Authors:  Olga Papazisi; Meindert Palmen; A H Jan Danser
Journal:  Cardiovasc Drugs Ther       Date:  2020-10-21       Impact factor: 3.947

6.  Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial.

Authors:  Olga Papazisi; Eline F Bruggemans; Remco R Berendsen; Juan D V Hugo; Jan H N Lindeman; Saskia L M A Beeres; M Sesmu Arbous; Wilbert B van den Hout; Bart J A Mertens; Can Ince; Robert J M Klautz; Meindert Palmen
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

7.  Determinants and Outcomes of Vasoplegia Following Left Ventricular Assist Device Implantation.

Authors:  Kristen M Tecson; Brian Lima; Andy Y Lee; Fayez S Raza; Grace Ching; Cheng-Han Lee; Joost Felius; Ronald D Baxter; Sasha Still; Justin D G Collier; Shelley A Hall; Susan M Joseph
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

8.  Vasoresponsiveness in patients with heart failure (VASOR): protocol for a prospective observational study.

Authors:  Marieke E van Vessem; Saskia L M A Beeres; Rob B P de Wilde; René de Vries; Remco R Berendsen; Evert de Jonge; A H Jan Danser; Robert J M Klautz; Martin J Schalij; Meindert Palmen
Journal:  J Cardiothorac Surg       Date:  2019-11-21       Impact factor: 1.637

9.  The additional use of methylene blue has a decatecholaminisation effect on cardiac vasoplegic syndrome after cardiac surgery.

Authors:  Walter Petermichl; Michael Gruber; Ina Schoeller; Kwahle Allouch; Bernhard M Graf; York A Zausig
Journal:  J Cardiothorac Surg       Date:  2021-07-28       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.